Enveric Biosciences Inc. (ENVB)
NASDAQ: ENVB
· Real-Time Price · USD
0.59
0.01 (1.32%)
At close: Sep 24, 2025, 3:58 PM
0.59
0.32%
Pre-market: Sep 25, 2025, 08:06 AM EDT
1.32% (1D)
| Bid | 0.56 |
| Market Cap | 1.45M |
| Revenue (ttm) | 340.38K |
| Net Income (ttm) | -9.94M |
| EPS (ttm) | -9.97 |
| PE Ratio (ttm) | -0.06 |
| Forward PE | -0.02 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.59 |
| Volume | 262,604 |
| Avg. Volume (20D) | 322,171 |
| Open | 0.59 |
| Previous Close | 0.58 |
| Day's Range | 0.57 - 0.59 |
| 52-Week Range | 0.56 - 124.88 |
| Beta | 0.37 |
| Ex-Dividend Date | n/a |
About ENVB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ENVB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ENVB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-29.3%
Enveric Biosciences shares are trading lower after...
Unlock content with
Pro Subscription
1 month ago
+8.2%
Shares of psychedelic companies are trading higher after a GOP senator stated he's "confident" that under the Trump administration, lawmakers will help secure alternative treatment options for military veterans, including access to psychedelic medicine.
3 weeks ago · businesswire.com
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MACAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychi...
